NASDAQ$TMDX
TransMedics Group Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
TransMedics reported fourth quarter financial results exceeding expectations, driven by the recovery of U.S. OCS Lung procedure volumes and progress with OCS DCD Heart and OCS Liver CAP clinical programs.
TransMedics Group, Inc. reported a net revenue of $7.6 million for the fourth quarter of 2020, representing a 26% increase compared to the fourth quarter of 2019. The increase was primarily due to the recovery of U.S. sales led by OCS Lung activities. The net loss for the quarter was $6.3 million, compared to $9.2 million in the same period in 2019.
- Net revenue reached $7.6 million, a 26% increase compared to Q4 2019.
- Gross margin improved to 63% from 62% in Q4 2019.
- Operating expenses decreased to $10.7 million from $12.4 million in Q4 2019.
- Net loss decreased to $6.3 million from $9.2 million in Q4 2019.
Headline financials
Revenue & EPS history
TransMedics · Revenue · Quarterly
$7.63M
Forward guidance
The company is focused on leveraging the progress made with the National OCS Program in 2020 and advancing FDA initiatives to accelerate growth through 2021 and beyond.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+4.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.6%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+42.6%
Q3 2023
Best reaction
-29.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.1% | -30.0% | -26.4% | |
| Q4 2025 | -4.6% | -3.6% | -35.1% | |
| Q3 2025 | +0.9% | -9.0% | +8.9% | |
| Q1 2025 | +19.6% | +31.3% | +49.2% | |
| Q4 2024 | +5.8% | -6.5% | -4.9% | |
| Q3 2024 | -29.3% | -34.2% | -30.4% | |
| Q2 2024 | +9.4% | +7.2% | +21.4% | |
| Q1 2024 | +20.9% | +31.6% | +40.3% | |
| Q4 2023 | +6.7% | -0.5% | -10.8% | |
| Q3 2023 | +42.6% | +34.6% | +73.5% | |
| Q2 2023 | -8.9% | -24.7% | -21.5% | |
| Q1 2023 | -6.7% | -6.4% | -8.1% | |
| Q4 2022 | +20.2% | +20.4% | +15.4% | |
| Q3 2022 | +20.7% | +17.6% | +38.7% | |
| Q2 2022 | -7.7% | +20.8% | +28.9% | |
| Q1 2022 | +39.5% | +25.4% | +29.5% | |
| Q4 2021 | +23.2% | +39.5% | +82.5% | |
| Q3 2021 | -12.0% | -16.3% | -29.0% | |
| Q2 2021 | +9.6% | +7.6% | +17.2% | |
| Q1 2021 | -12.6% | -15.1% | -11.3% | |
| Q4 2020 | +3.4% | -12.3% | +10.6% | |
| Q3 2020 | +4.8% | +10.6% | +20.8% | |
| Q2 2020 | +0.1% | -3.2% | -11.9% | |
| Q1 2020 | -7.6% | -0.6% | -11.7% | |
| Q4 2019 | -1.1% | -1.2% | -25.7% | |
| Q3 2019 | -14.2% | -13.0% | -1.7% | |
| Q2 2019 | -4.2% | -4.6% | +8.6% | |
| Q1 2019 | -2.3% | -2.1% | -4.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro